Mankind Pharma Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Mankind Pharma has appointed Rajkummar Rao as the brand ambassador for Nimulid Strong, a pain relief gel and spray. This partnership aims to position Nimulid Strong as a trusted solution for neck pain relief, emphasizing its quick action and effective formulation.

Rajkummar Rao Becomes Brand Ambassador for Nimulid Strong - 25 Jun, 2025

Mankind Pharma's consolidated net sales for March 2025 reached Rs 3,079.37 crore, up 26.15% year-on-year. However, net profit declined by 10.71% to Rs 420.77 crore, and EPS fell to Rs 10.20. EBITDA increased by 36.78%.

Mankind Pharma Reports Mixed Financial Results - 24 Jun, 2025

Mankind Pharma has launched a Father's Day campaign for HealthOK multivitamin tablets, celebrating fathers as HealthOK Heroes. The initiative emphasizes the importance of fathers' well-being and its connection to their children's health, supported by marketing across digital and traditional platforms.

Mankind Pharma Launches Father's Day Campaign - 13 Jun, 2025

Mankind Pharma has allotted 57,709 equity shares under its ESOP Plan, increasing its paid-up share capital. This move reflects the company's commitment to employee incentives.

Mankind Pharma Allocates Shares Under ESOP - 10 Jun, 2025

Mankind Pharma shares rose by 2% to Rs 2511.10, reflecting positive market sentiment. The company has shown consistent revenue and net profit growth, with a projected increase in EPS by 2025. Despite a bearish market sentiment noted on May 23, 2025, the stock's recent performance indicates resilience.

Mankind Pharma Shares Rise Amid Strong Financials - 30 May, 2025

Mankind Pharma aims to grow in gastrointestinal and dermatology segments, developing a novel anti-obesity drug, and enhancing its women's health portfolio post-BSV acquisition. The company targets 18-20% growth from BSV products and plans to strengthen its brand presence.

Mankind Pharma Expands Focus on Chronic Segments - 27 May, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Netprofit is up for the last 2 quarters, 380.23 Cr → 420.77 Cr (in ₹), with an average increase of 9.6% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Revenue is up for the last 5 quarters, 2.51K Cr → 3.33K Cr (in ₹), with an average increase of 6.6% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Retail Investor holdings remained unchanged at 2.90% of holdings in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Unchanged

In the last 1 month, MANKIND stock has moved down by -5.3%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

Promoters have decreased holdings from 72.71% to 72.70% in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Down

Mutual Funds have decreased holdings from 7.83% to 7.67% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

Foreign Institutions have decreased holdings from 13.34% to 12.92% in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Nifty Midcap 100

Nifty Midcap 150

BSE 500

Nifty 200

Nifty LargeMidcap 250

BSE Healthcare

BSE 200

S&P BSE 250 LargeMidCap

Nifty MidSmallcap 400

S&P BSE Largecap

S&P BSE 100 LargeCap TMC

NIFTY PHARMA

Nifty Healthcare

Nifty 500

SBI Bluechip Fund Direct Growth

HDFC Large Cap Fund -Direct Plan - Growth Option

Axis ELSS Tax Saver Fund Direct Plan Growth Option

SBI Contra Fund Direct Growth

SBI Magnum Midcap Fund Direct Growth

Mankind Pharma Ltd’s net profit fell -10.71% since last year same period to ₹420.77Cr in the Q4 2024-2025. On a quarterly growth basis, Mankind Pharma Ltd has generated 10.66% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	0.02	Bullish
CCI (20)	-591.29	Bullish
RSI (14)	54.2	Neutral
Momentum (10)	1.3	Bearish
ADI (14)	24.39	Neutral
Ultimate Oscillator (7,14,28)	72.05	Bullish

Name	Value	Action
SMA (20)	2384.63	Bullish
EMA (20)	2384.41	Bullish
VWMA (20)	2384.27	Bullish
SMA (50)	2384.95	Bullish
EMA (50)	2384.52	Bullish
SMA (200)	2385.93	Bearish
EMA (200)	2378.05	Bullish
KAMA (200)	2386.36	Bearish
DEMA (200)	2396.47	Bearish

Mankind Pharma Ltd (MANKIND)

Summary

Overall

Oscillators

Moving Averages